This study demonstrates the efficacy of ZIKV strain MR766 in solid neuroblastoma tumors by inducing a rapid tumoricidal effect with no evidence of recurrence, regardless of their status as a high-risk MYCN-amplified or posttreatment recurrent tumor. Here, MYCN is linked to neoplasm.